Table 2. Patient Characteristics .... | American Society of Hematology

Table 2.

Patient Characteristics

	Eligible Patients		Protocol Patients		Nonprotocol Patients
	N (259)	%^3-150	N (218)	%^3-150	N (41)	%^3-150
Sex
Boys	144	56	123	56	21	51
Girls	115	44	95	44	20	49
Age (yrs)
<1	3	1	3	1	0	0
1-9	213	82	177	81	36	88
≥10	43	17	38	17	5	12
Risk factor
<0.8	101	40	82	38	19	58
0.8-1.2	84	33	76	35	8	24
1.2-1.7	58	23	52	24	6	18
≥1.7	8	3	8	4	0	0
Unknown	8		0		8
Hb (mmol/L)
<5	140	54	118	54	22	54
≥5	118	46	99	45	19	46
Unknown	1		1		0
WBC (×10⁹/L)
<10	121	47	95	44	26	63
10-<50	89	34	77	35	12	29
50-<100	23	9	21	10	2	5
≥100	26	10	25	11	1	2
Platelets (×10⁹/L)
<50	122	47	103	47	19	46
50-<100	61	24	54	25	7	17
≥100	75	29	60	28	15	37
Unknown	1		1		0
CNS disease	5	2	5	2	0	0
Mediastinal mass	21	8	19	9	2	5
FAB
L1	196	76	166	76	30	73
L2	57	22	47	22	10	24
L3	0	0	0	0	0	0
AUL	4	2	3	2	1	2
Unknown	2		2		0
Immunophenotype
AUL	0	0	0	0	0	0
Pro-B-ALL	10	4	10	5	0	0
C-ALL	141	58	115	55	26	70
Pre-B-ALL	57	23	48	23	9	25
T-ALL	36	15	34	16	2	5
Other	1	0	1	0	0	0
Not determined	14		10		4
Cellploidy^3-150
Diploid	35	20	30	21	5	15
Hypodiploid <46	7	4	5	4	2	6
Hyperdiploid 47-50	23	13	17	12	6	18
Hyperdiploid >50 chr	55	32	44	31	11	33
Pseudodiploid	49	28	41	29	8	24
Polyploid	3	2	2	1	1	3
Not evaluable^3-151	57		55		2
Not determined	30		24		6
DNA index^3-150
<1.16	118	75	114	75	4	67
≥1.16	40	25	38	25	2	33
Not determined	101		66		35
Chromosome structural anomalies^3-150
Absent	54	35	45	36	9	30
Present	100	65	79	64	21	70
Not evaluable	75		70		5
Not determined	30		24		6
Down’s syndrome	6	2	4	2	2	5
Prednison response on day 8^3-150
<1,000 blasts/μL			198	94
≥1,000 blasts/μL			12	6
Unknown			8

	Eligible Patients		Protocol Patients		Nonprotocol Patients
	N (259)	%^3-150	N (218)	%^3-150	N (41)	%^3-150
Sex
Boys	144	56	123	56	21	51
Girls	115	44	95	44	20	49
Age (yrs)
<1	3	1	3	1	0	0
1-9	213	82	177	81	36	88
≥10	43	17	38	17	5	12
Risk factor
<0.8	101	40	82	38	19	58
0.8-1.2	84	33	76	35	8	24
1.2-1.7	58	23	52	24	6	18
≥1.7	8	3	8	4	0	0
Unknown	8		0		8
Hb (mmol/L)
<5	140	54	118	54	22	54
≥5	118	46	99	45	19	46
Unknown	1		1		0
WBC (×10⁹/L)
<10	121	47	95	44	26	63
10-<50	89	34	77	35	12	29
50-<100	23	9	21	10	2	5
≥100	26	10	25	11	1	2
Platelets (×10⁹/L)
<50	122	47	103	47	19	46
50-<100	61	24	54	25	7	17
≥100	75	29	60	28	15	37
Unknown	1		1		0
CNS disease	5	2	5	2	0	0
Mediastinal mass	21	8	19	9	2	5
FAB
L1	196	76	166	76	30	73
L2	57	22	47	22	10	24
L3	0	0	0	0	0	0
AUL	4	2	3	2	1	2
Unknown	2		2		0
Immunophenotype
AUL	0	0	0	0	0	0
Pro-B-ALL	10	4	10	5	0	0
C-ALL	141	58	115	55	26	70
Pre-B-ALL	57	23	48	23	9	25
T-ALL	36	15	34	16	2	5
Other	1	0	1	0	0	0
Not determined	14		10		4
Cellploidy^3-150
Diploid	35	20	30	21	5	15
Hypodiploid <46	7	4	5	4	2	6
Hyperdiploid 47-50	23	13	17	12	6	18
Hyperdiploid >50 chr	55	32	44	31	11	33
Pseudodiploid	49	28	41	29	8	24
Polyploid	3	2	2	1	1	3
Not evaluable^3-151	57		55		2
Not determined	30		24		6
DNA index^3-150
<1.16	118	75	114	75	4	67
≥1.16	40	25	38	25	2	33
Not determined	101		66		35
Chromosome structural anomalies^3-150
Absent	54	35	45	36	9	30
Present	100	65	79	64	21	70
Not evaluable	75		70		5
Not determined	30		24		6
Down’s syndrome	6	2	4	2	2	5
Prednison response on day 8^3-150
<1,000 blasts/μL			198	94
≥1,000 blasts/μL			12	6
Unknown			8

Percentage of patients with available information.

Including Down’s syndrome.